NexoBrid
- NexoBrid Werkzame stof
- concentraat van proteolytische enzymen verrijkt met bromelaïne
- Toepassing
- wondreiniging
- Alternatieven
- geen
What is this? NexoBrid is a medicine used to clean burns. It contains enzymes from pineapple that help remove dead skin.
What's happening? There is a shortage of NexoBrid in the EU. Supplies may be limited or hard to find.
Does this affect me? If you need NexoBrid for a burn, talk to your doctor or pharmacist right away.
What should I do? Ask your pharmacist or doctor about other treatments while supplies are low.
🤖 Deze begrijpelijke samenvatting wordt automatisch gegenereerd vanuit de officiële mededeling van de instantie met behulp van AI. Het is uitsluitend bedoeld voor algemene informatie — niet als medisch advies. Raadpleeg voor beslissingen over uw gezondheid altijd een apotheker of arts en lees de officiële bron hieronder.
📋 Van de officiële mededeling van de instantie
Bijgewerkt 1 week geleden- Eerst gepubliceerd
- 06/05/2026
- Geneesmiddelen die zijn getroffen
- NexoBrid
- Tekortstatus
- Ongoing
- Therapeutisch gebied (MeSH)
- Debridement
- Beschikbaarheid van alternatieven
- No
- Internationale niet-eigendomeinnaam (INN) of gangbare naam
- concentrate of proteolytic enzymes enriched in bromelain
Inhoud van de pagina
Tekortinformatie
There is a shortage of NexoBrid in some EU/EEA Member States.
NexoBrid is a medicine used for removing eschar (dead tissue which is dried out, thick, leathery and black) due to skin burns caused by heat or fire.
For further information on the use of the medicine, please refer to the medicine’s overview page.
In October 2025, MediWound Ltd., the manufacturer of NexoBrid, found a problem with a test used to check that the production of NexoBrid 5 g is sterile (clean and free from germs). The company is investigating the issue and, as a precautionary measure, has temporarily suspended the distribution of NexoBrid 5 g in the EU.
This has resulted in a temporary shortage of NexoBrid. In addition, the company has withdrawn NexoBrid 2 g from the EU market due to commercial reasons.
The shortage affects some of the Member States where the product is marketed: Austria, Belgium, Denmark, Finland, Germany, Italy, Norway, the Netherlands, Poland, Romania, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- If NexoBrid is not available, patients should be managed according to standard of care for wound treatment, including appropriate surgical debridement where indicated and the use of suitable wound dressings. Clinical management should be based on individual patient needs and current clinical guidelines.
- For additional information consult your country’s shortage register or contact your national competent authority.
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- While the medicine is not available, your doctor will treat your wound according to standard guidelines for wound care. This usually includes careful cleaning of the wound by a healthcare professional and the use of appropriate dressings to support healing.
- Follow your healthcare provider’s advice for ongoing wound care and monitoring.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Reden voor tekort
In October 2025, MediWound Ltd., the manufacturer of NexoBrid, found a problem with a test used to check that the production of NexoBrid 5 g is sterile (clean and free from germs). The company is investigating the issue and, as a precautionary measure, has temporarily suspended the distribution of NexoBrid 5 g in the EU.
This has resulted in a temporary shortage of NexoBrid. In addition, the company has withdrawn NexoBrid 2 g from the EU market due to commercial reasons.
Lidstaten die getroffen zijn
The shortage affects some of the Member States where the product is marketed: Austria, Belgium, Denmark, Finland, Germany, Italy, Norway, the Netherlands, Poland, Romania, Spain and Sweden.
This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority using the below links.
Monitoring van tekorten
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party Supports EMA’s MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Aanbevelingen voor zorgprofessionals
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- If NexoBrid is not available, patients should be managed according to standard of care for wound treatment, including appropriate surgical debridement where indicated and the use of suitable wound dressings. Clinical management should be based on individual patient needs and current clinical guidelines.
- For additional information consult your country’s shortage register or contact your national competent authority.
Aanbevelingen voor patiënten en mantelzorgers
- There is an ongoing shortage of NexoBrid in some EU/EEA Member States which is expected to last until June 2026.
- While the medicine is not available, your doctor will treat your wound according to standard guidelines for wound care. This usually includes careful cleaning of the wound by a healthcare professional and the use of appropriate dressings to support healing.
- Follow your healthcare provider’s advice for ongoing wound care and monitoring.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority using the below links.
Belangrijkste feiten
- Medicines affected
- NexoBrid
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- concentrate of proteolytic enzymes enriched in bromelain
- Therapeutic area (MESH)
- Debridement
- Availability of alternatives
- No
Belangrijke data
- First published
Medische informatie
🔬 Medische / technische details voor professionals
INN: concentrate of proteolytic enzymes enriched in bromelain · Area: Debridement · Alternatives: No
Alle informatie op deze pagina komt van de officiële mededeling van de instantie. Wij vertalen en vatten deze samen; wij voegen geen feiten toe of wijzigen deze.
